TAG:
ameripath
Year’s Ten Biggest Stories Reveal Modest Changes
By Robert Michel | From the Volume VII No. 17 – December 4, 2000 Issue
CEO SUMMARY: In many ways, 2000 was a relatively quiet year for laboratory organizations. This list of the ten biggest stories in the lab industry for 2000 demonstrates that the most innovative laboratory organizations in the United States are “raising the bar” for service and quality…
Prognostic versus Diagnostic Lab Medicine
By R. Lewis Dark | From the Volume VII No. 16 – November 13, 2000 Issue
MOST OF YOU ARE FAMILIAR WITH THE RACE TO DEVELOP effective laboratory tests and pharmaceuticals based on rapidly-developing genetic and molecular knowledge. We all ask the same question: when will my laboratory have to buy this technology and offer these new tests? For most of us, the answer is “…
AmeriPath Will Acquire Inform DX for $44.6 Mil
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: It’s another example of consolidation in the anatomic pathology marketplace. AmeriPath, Inc.’s acquisition of Inform DX, Inc. positions the company to do as much as $350 million in revenues next year. By acquiring Inform DX, AmeriPath also gains entry into six more states…
AmeriPath & InformDX Merging To Form Largest Anatomic Pathology Firm in U.S.
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: AmeriPath and InformDX shared several common elements in their respective business strategies. Both companies believe that pathology services are best delivered at the local level and benefit from the support of a national organization. Both companies believe that physicians …
Successful Specialty IPO Can Open Door for Others
By Robert Michel | From the Volume VII No. 14 – October 2, 2000 Issue
CEO SUMMARY: It’s no secret that a handful of laboratory companies would like to complete an initial public offering (IPO). If Specialty Labs’ public offering goes well, expect these lab companies to bring their own stock offerings to the public equity markets. As the number of public…
Bill Bonello Sees Opportunities In Diagnostic Services Companies
By Robert Michel | From the Volume VII No. 14 – October 2, 2000 Issue
CEO SUMMARY: With the clinical laboratory industry now enjoying growing interest by professional investors, THE DARK REPORT traveled to New York City to meet with financial analyst William B. Bonello, of U S Bancorp Piper Jaffray. Bonello co-authored a just-released overview of what he ca…
National Anatomic Pathology Companies Continue to Grow
By Robert Michel | From the Volume VII No. 13 – September 11, 2000 Issue
IT’S BOOM TIME IN ONE SEGMENT of the clinical laboratory world. The national anatomic pathology companies are posting record rates of growth and profits. The sustained and strong financial performance at DIANON Systems, Inc. and IMPATH, Inc. has not gone unnoticed…
IMPATH, AmeriPath, LabOne, MedTox, Genomics Collaborative, PharmChem, CARESIDE, Luminex, Fisher Scientific
By Robert Michel | From the Volume VII No. 12 – August 21, 2000 Issue
EMERGING BUSINESS OPPORTUNITY IN TISSUE BANKS & CANCER DATA EVEN AS THE HEALTHCARE SYSTEM squeezes pathologist incomes in a variety of specific professional services, it opens up business opportunities in other segments of the pathology field. Researchers and pharmaceutical companies wa…
Investors Returning To Lab Industry
By R. Lewis Dark | From the Volume VII No. 9 – June 19, 2000 Issue
SOMETHING BIG IS HAPPENING to the clinical laboratory industry and the anatomic pathology profession. For the first time in six or seven years, the investment community is paying close attention to the laboratory industry. This should be a welcome development for commercial lab owners and anatomic …
Merger Creates “New” Pathology Competitor
By Robert Michel | From the Volume VII No. 9 – June 19, 2000 Issue
CEO SUMMARY: Pathology business consolidation and regionalization continues. Pathology Consultants of America, Inc. (PCA) and PathSOURCE, Inc. announced their intention to merge last month. The combined company will be called Inform DX, Inc. and will compete nationally for anatomic pathol…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized